BMS CA209-812
Randomized, Open-Label, Phase 3 Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advnaced Stage Classical Hodgkin's Lymphoma (CheckMate 812: CHECKpoint Pathway and nivoluMab Clinical Trial Evaluation 812)
More Information
PCYC-1141-CA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab Versus Placebo in Combination With Rituximab in Treatment Naive Subjects With Follicular Lymphoma
More Information
S1608
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
More Information